ACRES announced Phase 3 of its Site Accreditation and Standards Initiative
The Alliance for Clinical Research Excellence and Safety (ACRES), a multi-stakeholder non-profit collaborative building a global system to enhance safety, quality and efficiency in clinical research, announced Phase 3 of its Site Accreditation and Standards Initiative (SASI). The third phase of the project begins formal development of standards and metrics for site accreditation. Teams of 5-7 experts drawn from the global stakeholder community will develop standards in at least seven domains: personnel, facilities, management, information systems, quality management, recruitment and enrollment, and research integrity. Additional cross-cutting teams in specialty areas, such as first-in-man studies and pediatrics will also contribute their expertise. The Global Standards Excellence (GSE) Working Party will be responsible for coordinating and integrating the standards development process. ACRES ally, Essex Management, will provide project support. Amir H. Kalali, Vice-President, Global Head, Neuroscience Center of Excellence at Quintiles and Arti Bajpai, President, Compliance and Quality Integration (CQI) Consulting will lead the effort as co-chairs of the GSE Working Party that will include experts with expertise in all aspects of clinical research site management and operations, quality management, and regulatory oversight from around the world.
Read the full release here.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
Obe-Cel Achieves High Response Rates, Durable Outcomes in r/r B-Cell Acute Lymphoblastic Leukemia
December 3rd 2024CAR T-cell therapy obecabtagene autoleucel produced high response rates, durable outcomes, and low toxicity in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia, especially benefiting those with low-to-intermediate bone marrow burden.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Opdivo plus Yervoy Significantly Outperforms Chemotherapy in MSI-H/dMMR Metastatic Colorectal Cancer
December 2nd 2024Phase III CheckMate 8HW trial results demonstrated that the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) significantly improves progression-free survival and has a better safety profile compared to chemotherapy in the first-line treatment of MSI-H or dMMR metastatic colorectal cancer.